BIOMARKER:

RET rearrangement

Entrez ID:

Related biomarkers:

‹

›

RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	cabozantinib tablet Sensitive: A2 - Guideline	cabozantinib tablet Sensitive: A2 - Guideline
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	vandetanib Sensitive: A2 - Guideline	vandetanib Sensitive: A2 - Guideline
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A2 - Guideline	selpercatinib Sensitive: A2 - Guideline
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A2 - Guideline	pralsetinib Sensitive: A2 - Guideline
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C2 – Inclusion Criteria	alectinib Sensitive: C2 – Inclusion Criteria
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	sunitinib Sensitive: C2 – Inclusion Criteria	sunitinib Sensitive: C2 – Inclusion Criteria
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	selpercatinib + pralsetinib Sensitive: C3 – Early Trials	selpercatinib + pralsetinib Sensitive: C3 – Early Trials
RET rearrangement RET rearrangement	Lung Adenocarcinoma LUAD	RET rearrangement RET rearrangement	Lung Adenocarcinoma LUAD	cabozantinib tablet Sensitive: C3 – Early Trials	cabozantinib tablet Sensitive: C3 – Early Trials
RET rearrangement RET rearrangement	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	RET rearrangement RET rearrangement	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	selumetinib Sensitive: D – Preclinical	selumetinib Sensitive: D – Preclinical
RET rearrangement RET rearrangement	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	RET rearrangement RET rearrangement	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical	MK-2206 Sensitive: D – Preclinical
RET rearrangement RET rearrangement	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	RET rearrangement RET rearrangement	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	AZD1480 Sensitive: D – Preclinical	AZD1480 Sensitive: D – Preclinical